ICER issues final evidence report on CAR T therapies with policy recommendations

After the Institute for Clinical and Economic Review's California Technology Assessment Forum held a public meeting to discuss the comparative effectiveness and value of CAR T therapies, the institute released a final evidence report with policy recommendations to ensure patient access to Kymriah tisagenlecleucel and Yescarta axicabtagene ciloleucel.

At the meeting, CTAF voted that the value of Kymriah from Novartis AG (NYSE:NVS; SIX:NOVN) was intermediate, while the panel was mixed on whether the value of Yescarta from the Kite Pharma Inc. unit of Gilead Sciences Inc. (NASDAQ:GILD) was intermediate or low...